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ABSTRACT 
66 female SLE patients, attending LUPUS CLINIC at Groote Schuur 
Hospital, were investigated for the presence of pulmonary 
involvement and specifically for evidence of pulmonary 
hypertension. The study of the relationship of pulmonary 
hypertension with the presence and severity of Raynaud's 
phenomenon, and with disease activity formed the main aim of the 
study. A literature review of primary pulmonary hypertension and 
pulmonary hypertension in systemic lupus erythematosus is 
presented. 
The mean pulmonary artery pressure of the study patients 
calculated from measurements made during echocardiography was 
25.9 mm Hg (SD=l0.8, range=6 - 52), and differed significantly from 
the 20 control subjects:15.72 mm Hg (SD=5.59, 6-28; p<0.0001). 
41 patients (62%) were classified as possibly having pulmonary 
hypertension by combined clinical, radiological, 
electrocardiographic and echocardiographic criteria. 12 of these 
patients were considered to have definite primary pulmonary 
hypertension, and a further 18 had probable primary pulmonary 
hypertension. 11 had pulmonary hypertension secondary to cardiac 
disease (3), fibrosing alveolitis (7) and recurrent pulmonary 
thromboembolism (1). Total ARA criteria differed significantly 
between these groups, but this assessment could have been 
influenced by observer bias. No association was found between the 
category of pulmonary hypertension and presence of Raynaud's 
phenomenon, or SLE disease activity score. Possible reasons for 
this lack of association are discussed. 
Other forms of pulmonary involvement found were pulmonary 
infections in 38 patients (57.6%), pleural involvement in 25 
(37.9%), cryptogenic fibrosing alveolitis in 9 (13.6%), asthma in 
6 (9%), vanishing lung syndrome in 3 (4.6%), acute lupus 
pneumonitis in 2 (3%), solitary pulmonary nodule in 2 (3%) and 
pulmonary hemorrhage, pulmonary thromboembolism, COAD and 
bronchiectasis in 1 each. In conclusion, suggested methods of 
treatment and future avenues of research are discussed. 
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Chapter 1 BACKGROUND 
1.1 Introduction 
Systemic Lupus Erythematosus (SLE) is a multisystem disorder 
characterised by multiple auto-antibodies that participate in 
immunologically mediated tissue and microvascular damage. The 
severity, and therefore the morbidity and mortality vary widely 
between patients. Primary Pulmonary Hypertension (PPH) has been 
recognised for several decades as a serious disorder of the 
pulmonary vasculature resulting in cor pulmonale and death. 
The co-existence of these two conditions has been documented more 
recently and, as might be expected, has been shown to be a 
particularly debilitating combination. Patients often present with 
advanced irreversible pulmonary vascular disease and palliative 
care is all that can be offered . 
Recent advances in non-invasive pulmonary artery pressure 
measurement using Doppler echocardiography has allowed earlier 
diagnosis of pulmonary hypertension . Knowledge about the 
pathogenetic mechanisms involved, has improved considerably in 
recent years. This has improved the prospect of developing 
effective forms of therapy that might influence the prognosis of 
affected patients . Several forms of treatment have been proposed 
with some being in regular use. 
1.2 Historical Perspective 
1 . 2.1 Primary Pulmonary Hypertension (PPH) 
In 1891 Romberg1 described the autopsy findings of a patient with 
sclerosed pulmonary arteries without underlying pulmonary or 
cardiac disease. This is thought to be the first description of 
PPH. 2 In 1951 Dresdale et al 3 described the clinical and 
hemodynamic findings in 39 patients with unexplained pulmonary 
hypertension and coined the term primary pulmonary hypertension . 
2 
In 1958 Wood4 proposed the hypothesis that PPH developed as a 
consequence of prolonged pulmonary vasoconstriction and suggested 
the use of vasodilator therapy. During the 1960s the publicity 
surrounding the appetite suppressant, Aminorex fumarate, as a 
cause of pulmonary hypertension, alerted the medical community to 
this condition in its various forms. 5 
In 1970 Wagenvoort and Wagenvoort 6 described the three 
histological subtypes of PPH: plexogenic, thrombotic and veno-
occlusive. In 1973 the current definition of PPH was proposed by 
the WH0. 7 In 1981 the National Institute of Health (NIH) funded 
the establishment of a registry for the study of PPH in America . 
Fors years, patients from 32 centers were enrolled and followed 
until 1989, thus providing very useful clinical and long term 
follow-up data. 8 
Treatment options for patients have been limited due to the 
advanced stage of the pathology by the time symptoms develop. In 
the 1980s and 1990s numerous reports of the use of vasodilators 
appeared. 9 - 13 The common finding of in situ thrombosis at post-
mortem has prompted the use of anticoagulants. 14 In the 1990s, 
heart-lung, single-, and double-lung transplantation has emerged 
as salvage therapy for advanced disease. 15 - 17 The lack of donors 
and cost of transplantation limit its widespread application. 
Early diagnosis and treatment, before irreversible heart failure 
occurs, remains the major objective of management and research 
protocols , 18 , 19 
1.2.2 Pulmonary Hypertension in Systemic Lupus Erythematosus 
In 1983 Hodson et a1 20 described the Cape Town experience with 4 
cases of Pulmonary Hypertension (PH) and SLE. These authors were 
able to find 17 cases of this association in the literature, the 
earliest being presented in 1964 in the case records of the 
Massachusetts General Hospital. 21 Several overseas groups have 
reported their experience with this association. 22 - 27 In these 
reports no alternative cause for the PH could be found, favouring 
the postulate that PPH occurs as a direct consequence of SLE. 
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1.3 Clinical Features of Primary Pulmonary Hypertension 
1.3.1 Definition 
PPH is defined by the World Health Organisation (WHO) as a mean 
pulmonary artery pressure of greater than 25 mm Hg at rest or 30 
mm Hg during exercise. 7 By definition there should be no 
demonstrable cardiac or pulmonary cause for the PH. 
1.3.2 History 
Dyspnea is the commonest presenting symptom, and was reported in 
90% of cases in the NIH registry. 8 The dyspnea worsens 
progressively as the disease advances, and is aggravated by 
hypoxemia-induced hyperventilation. 
Chest pain is a common symptom. As the coronary arteries are 
usually normal, it is probably due to relative underperfusion of 
the hypertrophied right ventricle, or due to stretching of the 
large pulmonary arteries. 
Syncope occurred in 10% of cases in the NIH registry. This usually 
occurred during or after exercise, and is probably due to a fixed 
cardiac output. Arrhythmias may also be responsible as severe 
hypotension can occur during atrial tachyarrhythmias. 
10% of the NIH patients had Raynaud's phenomenon. Hoarseness may 
occur due to compression of the recurrent laryngeal nerve by the 
enlarged pulmonary artery. Cough and hemoptysis are less frequent 
symptoms. 
At the onset of right ventricular failure, edema develops and 
upper gastro-intestinal congestive symptoms of distention, nausea, 
anorexia and wasting become prominent. 
4 
1.3.3 Examination 
In its early stages no signs are present. A loud pulmonary, and a 
narrowly split second heart sound, and a right ventricular heave 
are often the earliest signs. As the disease progresses, signs of 
right ventricular failure develop: edema, a raised venous pressure 
with CV waves, a pulsatile liver and the murmur of tricuspid 
regurgitation. Cyanosis is mild, unless a congenital heart defect 
has been missed, or re-opening of the foramen ovale has allowed 
right to left shunting. Clubbing is rare. 
1.3.4 Chest Radiograph (CXR) 
A CXR is an important part of the diagnostic work - up to exclude 
pulmonary or cardiac disease. The main and hilar pulmonary 
arteries were enlarged in 90 % and peripheral pulmonary arteries 
were pruned in 51 % of the NIH registry cases. The lung fields are 
usually clear. A normal CXR was found in 6 % of the cases with PH 
confirmed at cardiac catheterisation. 
In 1962 Chang28 reviewed the chest X-rays of 1085 normal subjects. 
He reported normal values for the diameter of the right descending 
pulmonary artery from its lateral aspect to the air column of the 
bronchus intermedius: 16 mm in males and 15 mm in females. This is 
measured on an inspiratory film and reduces by 1-3 mm in 
expiration. These measurements have been incorporated as normal 
values into radiology textbooks 29 - 31 and has been measured as part 
of this study. 
1.3.5 Electrocardiogram (ECG) 
ECG changes are usually only seen in advanced cases. The ECG 
abnormalities are mainly those of right ventricular and atrial 
enlargement: right axis deviation; right bundle branch block 
pattern; tall R waves, ST segment depression and inverted T waves 
in v1 -v2 ; and tall peaked p waves.3
2 
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1.3.6 Pulmonary Function Tests (PFT's) 
PFT's are performed to exclude obstructive or restrictive lung 
disease. Mild abnormalities in lung volumes are found due to 
increased stiffness of the lungs. 8 The transfer factor is often 
reduced. This is thought to be due to increased capillary-alveolar 
distance caused by the pulmonary vascular disease or a reduced 
pulmonary capillary bed. 
Hypoxemia is common and is due to ventilation-perfusion 
mismatches . In the occasional patient it is due to shunting 
through a patent foramen ovale . 
1.3.7 Perfusion lung scan 
The perfusion lung scan serves as the most useful, although not 
sensitive investigation for excluding recurrent pulmonary emboli 
as the cause of PH. 60 % of patients with PPH have abnormal 
ventilation/perfusion (VQ) scans, with mostly patchy defects, and 
in a minority, single subsegmental defects. Segmental and lobar 
defects are a feature of thromboembolism. 8 D'Alonzo et a1 33 were 
able to differentiate PPH from thromboembolic PH using VQ scans in 
25 cases studied. The former had low and the latter high 
probability scans. 
1.3.8 Pulmonary angiogram 
Some authors suggest performing pulmonary angiography when the 
lung scan shows single or multiple, segmental or lobar defects to 
confidently exclude pulmonary thromboembolism. 2 In PPH there is 
peripheral pruning of vessels with dilated central vessels, and in 
chronic thromboembolism there are cutoffs of large proximal 
vessels or filling defects. Because of the potential side effects 
of further increasing the pressure and even causing death, the 
procedure is controversial.3 4 
6 
1.3.9 Right heart study 
Cardiac catheterisation remains the gold standard for diagnosing 
PPH. It confidently excludes cardiac disease and allows accurate 
measurement of the pulmonary artery (PA) pressure. It is also 
possible to assess vascular responsiveness to vasodilators 
administered during the procedure. 19 , 35 This however, may on 
occassion cause severe hypotension. Cardiac catheterisation has a 
substantial mortality. The Mayo Clinic reported 5 deaths in 120 
patients studied for PH. 34 The NIH registry group had no deaths 
but severe hypotensive episodes or hemoptysis occurred in 10 of 
their patients. 8 
1.3.10 Echocardiogram 
Echocardiography has emerged as an important noninvasive 
diagnostic tool in PPH. It excludes cardiac causes of PH eg. 
silent mitral stenosis and intra-cardiac shunts . It allows 
visualisation of pulmonary valve motion and characteristic 
patterns have been described in PH: a rapid opening slope in 
systole, attenuation or absence of the "a" dip, 36 , 37 prolongation 
of the right ventricular pre-ejection period to right ventricular 
ejection time, 37 , 38 and midsystolic semi-closure of the pulmonary 
valve. 36, 37 
With the advent of doppler echocardiography, pulmonary artery 
pressure can now be quantified non-invasively and with acceptable 
accuracy. The doppler can often detect trivial tricuspid 
regurgitation (TR), and the measurement of the transtricuspid 
pressure gradient allows one to estimate the right ventricular 
systolic and pulmonary artery pressures. In a study by Chan et 
a1 39 this measurement correlated well with PA pressure measured by 
cardiac catheterisation (r=0,87). Adequate TR signals for pressure 
gradient estimation were found in 72 % of cases in their study. In 
other laboratories - including our institution - TR is often not 
detected, necessitating the use of other measurements for PA 
pressure estimation. 
7 
Kitabatake et a1 40 studied the doppler-derived blood flow 
characteristics in the right ventricular outflow tract of patients 
undergoing cardiac catheterisation. Cases with pulmonary 
hypertension had a rapid acceleration of flow velocity (AcT); a 
shortened right ventricular ejection time (RVET); and a reduced 
ratio of AcT/RVET. The AcT and ratio of AcT/RVET were correlated 
with the catheter data for mean pulmonary artery pressure by means 
of linear regression analysis. The measurements used were the 
average of readings from five to eleven consecutive cardiac cycles 
and importantly did not require the presence of TR. The 
log10 (MPAP) correlated in a linear fashion with these measures, 
with the following regression equations and correlation 
coefficients: 
Equation 1 : 
Equation 2: 
log1o(MPAP) = - 0.0068(AcT) + 2.1 
log1o(MPAP) = - 2.8(AcT/RVET) + 2.4 
Chan et al 39 used the following equation for MPAP: 
!Equation 3: MPAP = 79 - (0.45 x AcT). 
r=-0.88 
r=-0.90 
r=0.85 
The r-value was 0.66 but improved to 0.85 for heart rates between 
60 and 100. 
1.3.11 Magnetic Resonance Imaging (MRI) 
MRI with its excellent resolution has recently been used to 
estimate ventricular mass. Katz et al 41 were able to estimate 
accurately the ventricular mass of 10 fresh bovine hearts. In 
healthy volunteers and patients with PPH, the right ventricular 
myocardial mass was calculated from end-diastolic MRI images of 
the heart. An RV index - ratio of RV mass and body surface - was 
determined and correlated with the invasively measured PA pressure 
with the following regression equation and corrrelation 
coefficients: 
Mean PA pressure= 27.09 +(0.59 x RV index) r=0.75, p<0.003 
8 
1.3.12 Pathology 
Wagenvoort and Wagenvoort 6 described three histological subtypes 
of PPH: plexogenic pulmonary arteriopathy, recurrent 
microthromboembolism, and pulmonary veno-occlusive disease. The 
WH0 7 included these types in their position paper on PPH. A recent 
editorial by Rich42 questioned the distinction. Other workers in 
the field, however, are able to distinguish the subtypes on open 
lung biopsy43 , and found it helpful in categorising patients with 
unexplained PH. The increased morbidity of open lung biopsy in 
patients with PH has resulted in limited use of this 
investigation. 
Moser and Bloor44 caution against accepting a biopsy diagnosis of 
PPH on the basis of the presence of plexogenic and other 
characteristic findings. Several cases are sited where lung scans 
and angiograms identified evidence of chronic major vessel 
thromboembolism in the so-called PPH cases. Pulmonary 
thromboendarterectomy was performed on these patients with good 
results. 
1.4 Pathogenesis of Pulmonary Hypertension 
1.4.1 Primary Pulmonary Hypertension 
Many articles have been published which describe different 
individual mechanisms at play in PPH. The pathogenesis of PPH is, 
however, probably multifactorial. 
Wood considered pulmonary vasoconstriction to be an important 
pathogenetic factor. 4 The presence of Raynaud's phenomenon in 10 % 
of cases with PPH in the NIH registry, lent support to this 
hypothesis. 8 
9 
In 1988 at the 30th Aspen Lung Conference Hogg45 postulated that 
abnormal smooth muscle activation might result in reduced 
pulmonary vessel diameter, and a raised PA pressure. He suggested 
that it might be an abnormality of receptor or agonist-receptor 
interaction, but no proof of this was provided. 
In 1989 at the Third Grover Conference on the Pulmonary 
Circulation, Reid46 pointed out the importance of the endothelium. 
It acts as a monitor of homeostasis, and processes mediators on 
their way to the vessel wall, where they cause structural changes. 
Endothelin-1 (ET-1), a potent endothelial derived vasoconstrictor 
with mitogenic properties, has been the subject of various 
studies. Increased levels of ET-1 have been implicated in the 
pathogenesis of such varied disorders as the hepatorenal syndrome, 
diabetes mellitus, cardiogenic shock, and systemic and pulmonary 
hypertension. 
Stewart et a1 47 found increased circulating levels of ET-1 in all 
forms of PH. This could be due to increased release, or reduced 
clearance of ET-1. In PPH patients, a significantly increased 
arterial compared to venous level was found, suggesting increased 
pulmonary release or production of ET-1. The vascular damage found 
in secondary PH could result in reduced ET-1 clearance. 
Cacoub et a1 48 demonstrated increased venous ET-1 levels in PPH 
and in the Eisenmenger syndrome. In PPH mean ET-1 levels were 
higher, despite having lower PA pressures than the Eisenmenger 
syndrome group . A follow-up study by the same authors 49 using a 
radioimmunoassay for ET-1 levels in pulmonary tissue, demonstrated 
increased levels both in patients with PPH and the Eisenmenger 
syndrome compared to controls. 
10 
Giaid et a1 50 performed immunocytochemical analysis for the 
distribution of endothelin-1-like immunoreactivity on lung 
specimens. There was a significant increase in staining in the 
vascular endothelium of the PPH group, and to a lesser extent in 
the secondary PH group. The endothelium of elastic and muscular 
pulmonary arteries with severe medial thickening and intimal 
proliferation had the greatest degree of immunostaining. The 
staining was shown to a lesser extent in pulmonary capillaries and 
veins as well as bronchial arteries. No staining was found in 
systemic vessels of cases with PH and minimal staining was found 
in control lung specimens. 
Subsequently the authors demonstrated endothelin-1 messenger RNA 
by in situ hybridization. Its distribution matched closely that of 
the endothelin-1-like immunoreactivity in the lungs of patients 
with PH. This confirmed the hypothesis that increased ET-1 levels 
in cases with PH were due to its local production rather than 
reduced clearance. The initiating stimulus for this increased 
production is unknown. An unexpected finding was the expression of 
ET-1 in alveolar epithelial cells, which occurred almost 
exclusively in patients with pulmonary fibrosis. This suggested a 
role for ET-1 in other pulmonary diseases where cellular 
proliferation occurs. 
The presence of thrombi in the pulmonary vasculature of cases with 
PPH has already been mentioned. It may be formed in situ on a 
damaged endothelium via platelet-endothelium interactions.51 
Disordered fibrinolysis has been demonstrated in PPH by Eisenberg 
et al, 52 and this may result in reduced clearance of thrombi. 
Autoimmune mechanisms may play a role in PPH. The association of 
PPH with autoimmune disorders such as SLE favors this hypothesis. 
Raynaud's phenomenon, frequently found in autoimmune diseases, is 
also reported in PPH. 8 
11 
Many autoimmune diseases have an association with the human 
leukocyte antigen (HLA) class II determinants of the major 
histocompatibility complex (MHC). Barst et a1 53 found an increased 
incidence of DR3, DRw52, and DQw2, and a decreased DRS in children 
with PPH. In children with congenital heart disease with large 
shunts resulting in PH, no HLA association was found. In PPH, the 
specific MHC may be expressed on endothelial cells, and may lead 
to the induction of cytokines with resultant vascular smooth 
muscle changes. 
In animal models 54 of PH, inflammatory cells are prominent in 
vessel walls suggesting an immune basis for some of the vascular 
damage. This has not been found in human cases of PPH. The 
inflammatory phase of PPH may, however, have been missed if it 
occurs very early in the disease. 
Current researchers suggest that the endothelium is central to the 
pathogenesis of PPH. In a recent editoria155 Loscalzo states" 
that pulmonary endothelial dysfunction and abnormal vascular 
response have an important bearing on the pathogenesis, 
diagnosis, and treatment of pulmonary hypertension." He however 
points out, that it is unclear, whether this endothelial 
dysfunction is a cause, or consequence of the pulmonary 
hypertensive process. 
Pulmonary veno-occlusive disease is a rare form of PPH and is 
characterised by intimal proliferation and fibrosis of the 
intrapulmonary veins and venules. It has been described after 
viral illness, chemotherapy and toxins. 2 Very little is known 
about its pathogenesis. 
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1.4.2 Secondary Pulmonary Hypertension 
In more than 95% of cases of PH, it is secondary to cardiac, 
pulmonary or systemic disease. Olivari2 in a comprehensive review 
of PH classifies the causes and pathogenetic mechanisms as 
follows: 
a) Cardiac Disease 
i. Prolonged increased pulmonary flow exceeding the 
pulmonary vascular reserve, will result in excessive 
shear forces causing endothelial damage, intimal 
proliferation, medial hypertrophy and raised pulmonary 
vascular resistance, and is mediated by the same substances 
as PPH. This may occur in left to right shunts through 
ventricular and atrial septal defects, or a patent ductus 
arteriosus. 
ii. Increased resistance to pulmonary venous drainage with 
persistently elevated left atrial pressure results in 
PH. Such increased resistance occurs in: 
- left ventricular failure, eg. cardiomyopathy, 
valvular and ischemic heart disease 
- reduced LV compliance, eg. hypertension, 
hypertrophic cardiomyopathy 
- mitral valve disease, eg. mitral stenosis 
- left atrial myxoma and 
- pulmonary vein stenosis. 
b) Pulmonary Parenchymal Disease 
This is the commonest cause of PH in adults. Anatomical 
loss of pulmonary vessels, arteriolar constriction 
secondary to hypoxemia, and increased viscosity cause a 
raised pulmonary artery pressure. This occurs in chronic 
obstructive airways disease, restrictive lung disease, 
granulomatous disease, and cystic fibrosis. 
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c) Disease of Respiratory Function 
Alveolar hypoventilation with hypoxemia and acidosis 
results in pulmonary vasoconstriction and pulmonary 
hypertension. Examples of such diseases are: thoracic 
cage deformities, sleep apnea syndrome, obesity 
hypoventilation syndrome, and neuromuscular diseases. 
d) Pulmonary Vascular Disease 
Anatomical obstruction to pulmonary flow results in 
increased resistance and pulmonary artery pressure . This 
occurs in: pulmonary thromboembolism, pulmonary arteritis 
(Takayasu's disease), collagen vascular disease, sickle 
cell anemia, schistosomiasis, peripheral pulmonary 
artery stenosis, and high altitude. 
e) Miscellaneous causes with unclear mechanisms include: 
intravenous drug abuse, appetite suppressants, bush tea, 
and hepatic cirrhosis. 
1.4.3 Pulmonary Hypertension in Systemic Lupus Erythematosus 
The pathogenesis of pulmonary hypertension in SLE is unknown. 
Considering the range of microvascular pathologies and 
immunological phenomena found in this disease, a multifactorial 
aetiology is likely. Peripheral vasospasm (Raynaud's phenomenon) 
is a common early feature of SLE and may reflect a more general 
tendency to systemic vasospasm affecting organs such as the lungs. 
If this is indeed the case, it is possible that factors provoking 
Raynaud's phenomenon may provoke a transient increase in pulmonary 
vascular resistance. Furthermore, just as the changes in the 
fingers become fixed and permanent, so pulmonary vasospasm might 
become irreversible as a consequence of prolonged vasospasm . 
Several studies have been performed to investigate this 
relationship and hypotheses. 
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Cattle, with hyperreactive pulmonary vasculature, at an altitude 
of 1524 m, have been shown to develop PH when placed into a -5 °c 
chamber. 56 
Using single breath carbon monoxide transfer factor (TLCOsb) as an 
indicator of pulmonary blood volume, several investigators have 
shown changes during cold pressor testing in patients with 
Raynaud's phenomenon. Vergnon et a1 57 immersed the hands and 
forearms of subjects into 15 °c water and demonstrated a drop in 
TLCOsb in both patients with 1° and 2° Raynaud's, but not in 
controls. Fahey58 demonstrated a drop in a 1° Raynaud's group and 
no change in 2° Raynaud's or normal controls. Wise et al 59 used 
whole body immersion at 4 °c, and found no change in TLCOsb in 
cases with Raynaud's 2° to scleroderma, but found an increase in 
normals and 1° Raynaud's. This was interpreted as redistribution 
of blood from the peripheral to pulmonary circulation in the 
latter 2 groups. Due to pulmonary vascular disease in scleroderma 
group, the pulmonary vasculature could not accomodate the 
redistributed blood, thus explaining the unchanged TLCOsb· 
Miller60 , using hand immersion, demonstrated an increased TLCOsb 
in 1° Raunaud's, and no change in Raynaud's 2° to scleroderma, or 
in normals. The results from the latter two studies thus differed 
from the first two. It must, however, be noted that the numbers of 
patients were small, and the changes noted in TLCOsb were very 
small (albeit statistically significant). In addition, very few 
cases with SLE and no cases with PPH or PH were included in the 
above studies. Performing a similar study in patients with SLE and 
PH may shed more light on the link between peripheral and 
pulmonary vasospasm. 
The association of antiphospholipid antibodies and SLE is well 
known. Such patients have a tendency to arterial and venous 
thrombosis, and this may predispose to the development of PH in 
patients with SLE. 
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Immune complex deposition in vessel walls, or T cell mediated 
vascular injury with vasculitis, frequently occurs in SLE. When 
this occurs in the pulmonary vasculature, narrowing of the vessels 
may occur with consequent PH. Quismorio et a1 61 found immune 
complexes and vasculitis in pulmonary vasculature of patients with 
SLE and PH. Asherson et a1 25 suggest that this immune complex 
deposition demonstrated in the pulmonary vasculature is merely a 
reflection of its widespread deposition, and that it does not 
necessarily play a pathogenetic role . In a single case report, a 
patient with SLE and PH had a reduction in pulmonary artery 
pressure during a course of cyclophosphamide, which provides 
putative evidence for pulmonary vasculitis . 62 
Interstitial lung disease may occur in patients with SLE. In 
advanced disease, a combination of hypoxic pulmonary 
vasoconstriction and fibrotic damage of vessels may result in PH. 
1.5 Management of Primary Pulmonary Hypertension 
1 . 5.1 Exclude secondary causes 
The first step in the management of PPH is to confirm the 
diagnosis, ie. to exclude the secondary causes that are 
potentially treatable eg. mitral stenosis. 
Until more is known about the exact cause and relevant 
pathogenetic mechanisms, treatment is largely symptomatic and 
often using a "shotgun" approach. 
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1.5.2 Oxygen (02) therapy 
If hypoxemia is demonstrated, o2 supplementation should be 
considered to reduce pulmonary vasoconstriction, myocardial 
ischaemia and arrhythmias. 
1.5.3 Anticoagulants/antiplatelet agents 
Due to the frequent finding of thrombi in pulmonary vessels at 
autopsy, anticoagulants are widely used and are associated with 
improved survival when used alone14 , or in combination with 
vasodilators. 83 Antiplatelet agents may also be beneficial in 
reducing platelet aggregation and thrombosis, but may increase the 
risk of bleeding especially if they are combined with 
anticoagulants. 
1.5.4 Vasodilators 
Vasodilator agents remain the mainstay of PH treatment. Calcium 
channel blockers have been used with varying success. Controversy 
still exists over the need to confirm vasoresponsiveness. 63 This 
unfortunately entails performing cardiac catheterisation with its 
inherent risks to patients with raised PA pressure. Rich12 
recommended using high dose calcium channel blockers in 
hemodynamic testing, to identify responsive patients for long term 
treatment. Calcium channel blockers are, however, not without side 
effects, particularly hypotension. Noncardiogenic pulmonary edema, 
possibly due to leaky capillaries, has also been reported 
following the use of high doses of calcium channel blockers.64 
Adenosine reduces pulmonary vascular resistance and PA pressure.6 5 
It compares favorably to nifedipine11 and these drugs may be used 
in combination. 9 The disadvantage of adenosine is the lack of an 
oral formulation. 
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Uren et a1 10 demonstrated some reduction in pulmonary vascular 
resistance (PVR) and PA pressure with acetylcholine, calcitonin 
gene-related peptide and nicardipine, but no response to 
substance P. Apart from nicardipine, these agents are all 
endothelium-dependent vasodilators and administered parenterally. 
Prostaglandins cause vasodilation. In several forms of severe PH, 
including the toxic oil syndrome, a prostacycline-stable analogue 
(Iloprost) was infused with good effect. 66 Aerosolised 
prostacycline (PGI 2 ) similarly reduced the PA pressure in 
ventilated patients with the adult respiratory distress syndrome 
(ARDS) . 67 
Endothelium-derived relaxing factor (EDRF), a potent vasodilator, 
has been shown to be nitric oxide (NO). It is rapidly inactivated 
by binding with hemoglobin. When inhaled, it diffuses into the 
pulmonary interstitium and acts directly on the vascular smooth 
muscle, causing vasodilation and a reduced PA pressure. This has 
been demonstrated in sheep, 68 as well as in patients with ARDs,69 
severe PPH, 70 and chronic obstructive airways disease. 71 Currently 
it has limited clinical usefulness due to its rapid inactivation. 
Administration via inhalation is preferable to the oral or 
parenteral route as it acts locally on the diseased vasculature 
without systemic effects. 
1.5.5 Immunosuppression 
Immunosuppressive agents have been used for PPH when a collagen 
vascular disease is present. 62 The lack of effect in most patients 
is not unexpected, as little inflammation is evident in most cases 
assessd by open lung biopsy or at post-mortem examination. 
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1.5.6 Transplantation 
Transplantation has become a viable treatment option for advanced 
cases of PPH, with the recent improvements in treatment of 
rejection and improved surgical expertise. Parquin et a1 15 found 
no difference in the actuarial survival between heart lung and 
double lung transplantation for severe PPH. Frist et a1 16 
performed single lung transplantation on five patients with severe 
PH (two with PPH) and all were alive at mean follow-up of 412 
days. Despite severe preoperative right ventricular dysfunction, 
in all cases the pulmonary vascular resistance normalized, and 
full cardiac recovery occurred postoperatively. This may be 
attributed to the transplanted lung receiving >85 % of the cardiac 
output. In view of the universal shortage of organs, single lung 
transplantation is now the preferred surgical treatment . 
Higenbottam et a1 17 reported the survival data of 44 patients with 
PPH, treated with long term intravenous prostacycline while 
waiting for heart-lung transplantation. The patients were pre-
tested for vasoresponsiveness, and those with the least 
vasodilation, had the best survival figures when treated with 
prostacycline. At a glance this seems paradoxical, and contrasts 
with the survival data of vasodilators reported by Rich et a1 83 . 
The responsible mechanism is probably prostacycline's powerful 
inhibition of platelet aggregation, rather than vasodilation. The 
prostacycline reduced the monthly mortality risk by 66%, as 
compared to the 18% reduction achieved with heart-lung 
transplantation. The advantage to the patient of transplantation 
is that the constant intravenous infusion can be discontinued. 
Prostacycline however buys time in these patients for a donor to 
become available. 
In view of the poor survival rates of clinically evident PPH, 
better tests are required for earlier diagnosis of PPH. As the 
pathogenesis becomes known, more specific and practical 
therapeutic modalities may become available. 
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Chapter 2 STUDY 
2.1 Aim 
The aim of this study was to evaluate patients with SLE for 
pulmonary involvement - in particular the presence of pulmonary 
hypertension - and to investigate the relationship of peripheral 
vasospasm (Raynaud's phenomenon) to pulmonary vasospasm. 
2.2 Hypotheses 
The study tested the following hypotheses: 
1. Pulmonary hypertension is more common in SLE than previously 
recognised. 
2. Pulmonary hypertension is strongly associated with the 
presence of peripheral vasospasm in SLE . 
3. Pulmonary hypertension is associated with active SLE. 
2.3 Study Design 
A case study of patients attending LUPUS CLINIC over a 15 month 
period to determine the prevalence of pulmonary involvement 
including pulmonary hypertension and the associations mentioned 
above. 
2.4 Definitions 
The following criteria were used to define: 
2.4.1 Systemic Lupus Erythematosus 
At least 4 of following 11 American Rheumatism Association (ARA) 
Criteria 72 : 
1. Malar rash 
2. Discoid rash 
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3. Photosensitivity 
4. Oral ulcers 
5. Arthritis: non-erosive arthritis involving at least 2 or more 
peripheral joints 
6. Serositis: pleuritis - history, rub or effusion or 
pe~icarditis - rub, ECG or effusion 
7. Renal: persistent proteinuria > 0.5 g/day or 3+ on paper stick 
testing 
8. Neurologic: seizures or psychosis 
9. Haematologic: haemolytic anaemia with reticulocytosis or 
leucopenia <4000/mm3 or 
lymphopenia <1500/mm3 or 
thrombocytopenia <100 OOO/mm3 
10.Immunologic: increased anti-DNA antibody levels or 
increased ENA(Sm) or 
false positive serological test for syphilis 
for at least 6 months 
11.Anti-nuclear antibody (ANF): abnormal titre 
Patients with an overlap syndrome or a mixed connective tissue 
disease were excluded. 
2.4.2 Pulmonary Hypertension 
Major and minor criteria were used to define PH. 
Major criteria: 
1. Direct measurement by Swan Ganz catherization: 
mean PA pressure> 25 mm Hg 
2. Echocardiograph: mean PA pressure> 40 mm Hg 
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Minor criteria: 
1. Chest Radiograph: enlarged pulmonary arteries, right 
ventricle or both as judged by a 
chest radiologist 
2. Clinical features: one or more of palpable and/or loud 
P2, RV heave and/or RV failure 
3. Electrocardiograph: two or more of tall R in RV leads 
and AVR; deep Sin I,II,III; small 
q in Vl; RBBB; R axis; RV strain; 
and p > 1,5 mm tall 
4. Histology: hypertrophied pulmonary arteries/arterioles 
on open lung biopsy , or at autopsy, assessed 
on pathological criteria 
The pulmonary hypertension group was divided into: 
Definite pulmonary hypertension - At least one major 
criterion 
Probable pulmonary hypertension - Echo PAP : 20 - 40 
and 
1 or more minor 
criteria 
Possible pulmonary hypertension - Echo PAP: 20 - 40 
and 
no minor criteria 
Pulmonary hypertension was further subdivided into: 
Primary - absence of any known cause of pulmonary 
hypertension and 
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secondary - presence of one of the following conditions: 
Heart disease eg. mitral stenosis, L to R shunts 
Pulmonary thromboembolism 
Interstitial lung disease: 
radiographic diffuse infiltrate 
restrictive lung defect 
(FVC < 66 % predicted) 
TLCO < 66 % predicted 
biopsy evidence 
Obstructive lung disease: 
2.4.3 Pulmonary Involvement 
radiographic hyperinflation 
FEVl/FVC < 75 % predicted 
TLC> 120 % predicted 
RV/TLC> (predicted ratio+l0%) 
Acute infections: bronchial - cough productive of purulent 
sputum with no evidence of 
consolidation clinically or on 
CXR, and treated with antibiotics 
pneumonia - cough productive of purulent 
sputum with evidence of 
consolidation clinically or on CXR, 
usually requiring admission 
pulmonary tuberculosis - radiographic evidence 
and usually 
microbiological 
confirmation 
Pleural: pleuritic chest pain, pleural rub or pleural 
effusion (clinically or on CXR) 
Fibrosing alveolitis: dyspnea, clubbing and crackles, 
diffuse infiltrate on CXR, 
restriction on PFT's and reduced TLCO, 
and histological diagnosis (if available) 
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Pulmonary hemorrhage: hemoptysis presumed to be due to 
diffuse pulmonary vasculitis 
(capillaritis), once known causes of 
hemoptysis have been excluded 
Vanishing lung: diaphragmatic weakness as evidenced by 
small lung volumes clinically and on CXR, 
reduced maximum inspiratory and expiratory 
mouth pressures (MIP's and MEP's), 
and absence of interstitial involvement 
Bronchiectasis: chronic sputum production with crackles 
and CXR abnormality (ring shadows and 
tramlining) 
Acute lupus pneumonitis: acute dyspnea, crackles, pulmonary 
infiltrate on radiograph not due to 
fluid or infection, and rapid 
response to corticosteroids. 
2.4.4 Raynaud's Phenomenon 
A three colour change of the skin of the digits to white, blue or 
red, usually on cold exposure. 
2.4.5 Raynaud's Severity 
A visual analogue score was used to grade the patient's perception 
of the severity of peripheral vasospasm on the study- day. A score 
of O = no vasospasm up to 10 = extreme vasospasm was used. The 
grading took into account the current weather/temperature, the 
duration of vasospasm, and the severity of vasospasm as witnessed 
by colour changes and interference with hand function. 
2.4.6 The Physician's global assessment of disease activity 
Disease activity was graded on a visual analogue scale from O -
10. A score of O = inactive up to 10 = highly active was used, 
according to a combination of the following clinical and 
laboratory criteria. 
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Clinical criteria: Arthritis/arthralgias, Raynaud's phenomenon, 
active skin involvement, mouth ulcers, serositis, and 
neuropsychiatric manifestations. 
Laboratory criteria: Renal-proteinuria, and casts 
Hematologic-anemia, thrombocytopenia 
and leukopenia/lymphopenia 
Immunologic-increased immune complexes 
and hypocomplementemia 
2.4.7 Clinical, Radiographic, Physiologic (CRP) Score73 
0 = 
2 = 
4 = 
6 = 
8 = 
10 = 
12 = 
14 = 
16 = 
18 = 
20 = 
no dyspnea after 30 minutes activity 
5 flights of stairs , 10 minutes activity 
2 km level 3 flights of stairs 
400 m to 2 km level , 2 flights of stairs 
100 to 400 m level , bedmaking 
50 to 100 m level , 1 flight of stairs 
scrubbing I factory work 
15 to 50 m level I housework 
6 to 15 m level I light work 
walking < 6 m I minor effort I prolonged 
eating I writing 
at rest 
2.5 Methods 
2.5.1 Study Patients 
talking 
Female patients attending the weekly LUPUS CLINIC were recruited 
randomly by the investigator, and were fully evaluated for current 
pulmonary involvement. A current respiratory and rheumatological 
history was obtained and a clinical examination was performed . 
(See Appendix A) 
25 
2.5.2 Controls 
An echocardiogram was performed on age matched healthy female 
volunteers to ascertain a normal range for the PA pressure 
measurements using the AcT and RVET method. 
2.5.3 Laboratory Investigations 
Blood tests for serological and activity markers and the anti-
phospholipid antibody were performed if not previously performed 
in the preceeding 3 months. (See Appendix B) Urine dipstix and 
microscopy was performed. Urine results obtained at the previous 
visit were used if the patient was menstruating on the study day. 
2.5.4 Chest Radiograph 
A postero-anterior inspiratory CXR was performed on all the 
patients, using the same apparatus in the Respiratory Clinic 
Radiology Department. All current and available past chest films 
were reviewed by the same chest radiologist without any clinical 
or laboratory information. On the current film particular care was 
taken to measure the diameter of the right descending pulmonary 
artery . Pulmonary and cardiac abnormalities were recorded on the 
Data Sheet (Appendix A). 
2.5.5 Electrocardiogram {ECG) 
A standard twelve lead ECG was performed on a MAC 15 computerised 
ECG machine (Marquette Electronics Inc . ) and analysed for relevant 
abnormalities (See definitions) . 
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2.5.6 Pulmonary Function Tests 
A flow-volume loop and single breath carbon monoxide transfer 
factor (TLCOsb) were performed on the Masterlab Jaeger automated 
system, (Jaeger, Wurzburg). The American Thoracic Society (ATS) 
standardised criteria74 were adhered to. Volumes were reported in 
millilitres and as percentage predicted (% pred) using the 
predicted values of Schoenberg et al 75 and the TLCOsb predicted 
values were taken from Cotes. 76 The TLCOsb was corrected for 
hemoglobin using the formula of Cotes et al. 77 Results were 
further reported as normal, mild, moderate and severe. (See 
Appendix C) MIP's and MEP's were performed using a pressure gauge 
manometer as described by Black and Hyatt 7 8 . 
2.5.7 Echocardiogram (Echo) 
An echocardiogram was performed using a Hewlett Packard Sonos 500 
machine with a 2.5 MHz transducer. An M-mode echo was performed to 
identify any cardiac abnormality and measure the cardiac output. A 
continuous wave doppler was performed to identify TR and to 
estimate the PA pressure. In most cases the RV outflow tract was 
also sampled, and the pulmonary artery acceleration time (AcT) and 
right ventricular ejection time (RVET) during four to five cardiac 
cycles was recorded. See fig 2.1. The regression equation 3 
described in Chapter 1.3.10 was used to calculate the PA pressure. 
2.5.8 Folder Review 
Finally all available hospital and Lupus Clinic records were 
reviewed for past pulmonary involvement. 
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Figure 2.1 
Echocardiographic doppler tracing of pulmonary artery outflow 
tract to demonstrate the measurement of AcT and RVET 
MAXV =71.4 CM/5 
TIME =. 120 SEC 
ACC =585_ CM/52 
RVET 
I . 
AcT 
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2.5.9 Statistical Analysis 
A data sheet was used to record all data (see appendix A) and 
entered on the MRC computer. The SAS/BASE and SAS/STAT software 
(SAS Institute Inc, Cary, N.C., USA) was used for univariate and 
multivariate analysis by the MRC statisticians. For all analyses, 
p < 0.05 was considered to be statistically significant. Depending 
on the sample size, the Chi square approximation test was used for 
samples with more than 5 observations per cell, or the Fisher 
exact 2-tailed test for less than 5 observations per cell. 
2.6 Ethical Considerations and Funding 
Informed consent was obtained from all patients and control 
subjects included in the study. (Appendix D) Permission for the 
study was granted by the Ethics and Research Committee of the 
University of Cape Town Medical School. Funding was obtained from 
the Medical Research Council and the Nellie Atkinson fund. 
2.7 Results 
2.7.1 Study Period 
The study was conducted between November 1992 and February 1994 at 
the Lupus Clinic at Groote Schuur Hospital and the University of 
Cape Town, South Africa. Approximately 120 patients with SLE are 
regularly followed at this clinic which serves as the major 
academic referral centre in the Western Cape. 
2.7.2 Study Patients 
The study patients consisted of 66 females fulfilling 4 or more of 
the 1982 ARA criteria for SLE. There were 60 coloured and 6 black 
patients with a mean age of 39 years (SD=ll.5, range=l4.4-72.4). 
The mean disease duration was 9 years (SD=7.3, range=0.5-36.4). 3 
patients refused to participate in the study. 
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2.7.3 History 
Smoking History 
There were 31 life-time non-smokers. The 15 ex-smokers had a mean 
smoking history of 7.5 (SD=9.9) pack-years (range=l-30) and the 20 
current smokers had a mean history of 8.1 (10.1) pack-years 
(range=l-40). 
Respiratory History 
The mean CRP dyspnea score was 4. See Figure 2.1 
Number of 
patients 
Figure 2.1 
Mean dyspnea score 
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A dry cough occurred in 6 (7.1.%). 13 (15.5%) had a cough 
productive of mucoid sputum. In 7 (8.3%) it was purulent and in 3 
(3.6%) it was bloodstained during the preceeding 3 months. Some 
patients produced more than one type of sputum. 16 (19%) had been 
treated for bronchitis in the corresponding period and none were 
on anti-tuberculous treatment. Pleuritic chest pain was present on 
the study day in 20 patients (23.8%). 
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Rheumatological History 
On the study day 16 (24.2%) reported the presence of Raynaud's 
with a mean severity score of 2.6. (See Figure 2.3) A total of 38 
(57.6%) had reported Raynaud's phenomenon at some stage in their 
illness. 
Figyre 2.3 
Raynaud's severity 
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Raynaud's severity 
Photosensitivity was reported in 42 (63.6%) and 
arthritis/arthralgias in 46 (69.7%). Digital ulceration had 
occurred in the past in 11 (16.7%) and was present on the study 
day in 2 (3%) . 
Treatment 
Medications that had been, or were in use for the treatment of SLE 
and its complications are summarised in Table 2.1. 
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Table 2.1 
Medications used in study patients 
Medication Number of (% total} Duration SD Range 
patients in months 
Cortico-steroids 
current: 34 ( 51. 5) 49 44.2 5-216 
past: 28 (42.2) 47.8 59.8 9-336 
never: 16 ( 24. 2) 
Chloroquine 
current: 21 (31. 8) 32 29.2 3-129 
past: 16 (24.2) 
never: 31 (47) 
Azathioprine 
current: 3 ( 4. 5) 
Cyclophosphamide 
current: 5 ( 7. 6) 
past: 6 ( 9. 1) 
Warfarin 4 ( 6 .1) 
Aspirin 6 ( 9 .1) 
Vasodilators 5 ( 7. 6) 
2.7.4 Examination 
A malar rash was present in 8 (12.1%) and a discoid rash in 15 
(22.7%). None had painless oral ulceration. Raynaud's was observed 
in 15 (22.7%) and objective synovitis in 15 (22.7%). 
None had clubbing or a pleural rub, and 12 (18.2%) had end-
inspiratory crackles. 
Peripheral edema was found in 1 (1.5%), a raised JVP in 1 and an 
enlarged liver in 5 (7.6%). 
Signs of pulmonary hypertension are summarised in Table 2.2. 
Signs 
Palpable P2 
RV lift 
Loud P2 
TR 
Table 2.2 
Signs of PH 
Number of 
cases 
5 
7 
8 
0 
(% total} 
( 7. 6) 
(10.6) 
( 12 .1) 
( 0) 
7 had only one sign of pulmonary hypertension, 2 had two, and 3 
had three signs. 6 patients with clinically suspected PH had a 
normal PA pressure. (See figure 2.3) 
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Figure 2.4 
Correlation between signs of PH and measured PA pressure 
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2.7.5 Pulmonary Function Tests (Table 2.3) 
65 cases were able to perform PFT's. Results are shown in 
Table 2.3. 
Table 2.3 
Pulmonary function tests in 65 patients with SLE 
PFT: Mean SD Range %pred. 
FEVl 2110 512 1080-3000 84.4 
FVC 2598 569 1600-3790 85.5 
TLCO 15.64 3.72 6.07-25.1 64.7 
Hb corr. TLCO 17.54 4.02 7.18-26.67 72.3 
KCO 4.66 0.90 2.57-7.35 85.6 
MIP 62.4 23.5 25-125 75.71 
MEP 93.5 24.15 50-160 63.29 
These measurements were subdivided according to severity as shown 
in Table 2.4. 
Table 2.4 
Severity of abnormal PFTs 
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Normal ( % ) Mild ( % ) Moderate ( % ) Severe (%) 
[ cases (N) ] 
Restriction 46 (70.8) 15 (23.1) 3 ( 4. 6) 1 (1. 5) 
Obstruction 64 ( 8 7) 1 ( 1. 5) 0 ( 0) 0 ( 0) 
TLCO 13 ( 20) 27 (41.5) 23 (35. 4) 2 ( 3) 
TLCO corr. 22 (34.4) 26 (40.6) 16 (25) 0 ( 0) 
2.7.6 Electrocardiogram 
In 5 patients (7.6%) the ECG was abnormal. 1 had a RBBB pattern, 3 
had evidence of right atrial enlargement and 1 had right 
ventricular enlargement and strain pattern. None had more than one 
abnormality. The ECG abnormalities and corresponding PA pressures 
are shown in Figure 2.5. 
number 
of 
patients 
~ 
: 
Figure 2.5 
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2.7.7 Chest Radiograph 
D normal ECG 
~ abnormal 
ECG 
The commonest abnormalities were pleural fluid or thickening, 
noted in 23 (34.9%) and evidence of past tuberculosis in 8 
(12.1%). 6 (9.1%) had features of pulmonary hypertension, 5 (7.6%) 
of cryptogenic fibrosing alveolitis, and 1 (1.5%) of vanishing 
lung. 
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Other radiographic abnormalities noted were pericardial effusions 
in 4, fluid overload in 7, atelectasis in 2 and a calcified 
mediastinal node and accessory right inferior fissure in 1 case. 
2.7.8 Echocardiogram 
Study patients 
The echocardiogram was of very poor quality in 1 patient (1.5%) 
and the best estimate possible was a mean of 6 mm Hg which was 
used in the further analysis. Tricuspid regurgitation was present 
in 15 (23%) and in 9 the PA pressure could be estimated from it. 
This TR derived PA pressure measurement was used in the later 
analyses in only 4 patients where it was the only measurement 
available. In 2 the PA pressure was only reported as being< 19 
and a value of 19 was used. In the remainder the values derived 
from equation 3 (Chapter 1.3.10) using the AcT were used in the 
statistical analyses. 
The acceleration and ejection times were obtained from 4 to 5 
cardiac cycles and recorded in 49 patients and is shown in Table 
2 .5. 
Table 2.5 
Echocardiographic measurements 
Mean 
.ifil2l.. Range 
Study :gatients 
ACT 116 29.7 30-210 
RVET 284 44.8 140-420 
PA pressure 25.9 10.8 6-52 
Controls 
ACT 141 16.3 10-210 
RVET 304 32.3 210-380 
PA pressure 15.7 5.59 6-28 
The patients were divided into 3 groups according to the measured 
PA pressure. (fig 2.6) 
Controls 
Figure 2.6 
Pulmonary artery pressure groups 
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20 healthy age matched controls (mean age=38.2 ;range=22.2-72) 
consented to an echocardiogram. The echo failed in 1 due to poor 
PA doppler signals. None had tricuspid regurgitation. See Table 
2.5 for results. 
2.7.9 Blood results (Table 2.6) 
The results of the blood investigations are summarised in 
Table 2.6. 
Table 2.6 
Blood investigations 
Test Number Mean Range SD Abnormal g.. 
...2.. 
tested 
ANF 62 500* 0-2500 N/A 51 ( 82. 3) 
ENA 62 20 ooo* 160-160 000 N/A 59 ( 95. 2) 
Anti-DNA 65 20.28 0-139 28.68 21 (32. 3) 
CIC 61 12 2-77 14.5 34 (55. 7) 
C-RP 66 1. 5 0-8.1 1.6 39 (59 .1) 
CH50 60 184.5 70-300 77.5 24 (40) 
C3 46 97.2 30-166 30.2 14 ( 3 0. 4) 
C4 43 20.8 8-35 22.7 9 (20. 9) 
APL 61 13.2 0-98 21.3 (See text) 
Hb 65 11.4 7.4-18 1. 9 13 ( 20) 
wee 65 6454 1900-18100 2902 14 (21.5) 
Lymph's 62 1534 132-4163 1015 34 (54.8) 
Platelets 65 281523 74000-684000 113134 4 (6 .2) 
(*=Median value given) 
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36 patients (59%) had a normal APL-IGG titre. 12 (19.7%) had a low 
titre, 13 (21.3%) a moderate titre and none a high titre. 
2.7.10 Physician's global assessment of disease activity(Fig. 2.7) 
The mean disease activity count was 3 ranging from 1 to 7. 
Figure 2.7 
Physician's global assessment of disease activity 
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2.7.11 ARA Criteria (Figure 2.8) 
The mean total criteria was 6. The commonest clinical ARA criteria 
were: arthritis in 54 (81.8%), photosensitivity in 42 (63.6%) and 
a malar rash in 36 (54.5%). The commonest laboratory criteria were 
positive ANF in 65 (98.5%), ENA in 64 (97%) and lymphopenia in 36 
(54.5%). 
13 
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Figure 2.8 
ARA criteria 
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2.7.12 Outpatient Visits/Admissions 
37 
7 
I 2 I 1 ~ Q 
8 9 10 11 
criteria 
The patients had attended Lupus Clinic for a mean of 43.1 visits 
(range=2-267) for a mean duration of 7 years (range=0.1-34.7). 
Only 7 patients had never been admitted to hospital. The mean 
number of admissions for SLE related illnesses was 3.2 (range=0-
14) . 
2.7.13 a) Pulmonary Hypertension - possible, probable or definite 
(fig 2.9) 
41 patients (62%) were classified as having possible, probable or 
definite PH by combined clinical, radiological, ECG and 
echocardiographic criteria as defined in Chapter 2.4.2. 
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Figure 2.9 
Pulmonary hypertension groups according to combined clinical, 
radiological, ECG and echocardiographic criteria 
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2.7.13 b) Primary and secondary pulmonary hypertension (fig 2.10) 
Definite Primary Pulmonary Hypertension 
12 of the 41 patients considered to have possible, probable or 
definite PH were classified as definite primary pulmonary 
hypertension on the basis of a negative perfusion scan and no 
secondary cause being present. 
Probable Primary Pulmonary Hypertension 
18 cases could be placed in the probable PPH group as no secondary 
cause was present, and there was a very low clinical index of 
suspicion of thromboembolism in them, but perfusion lung scans had 
not been performed. 
39 
Secondary Pulmonary Hypertension 
11 patients were classified in the secondary pulmonary 
hypertension group. 3 patients were secondary to cardiac disease 
on the basis of echo features of diastolic dysfunction. 7 patients 
had CFA and 1 had recurrent thromboembolism. 
Figure 2.10 
Primary and Secondary Pulmonary Hypertension 
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2.7.13 c) Clinical features of patients with PH 
Of the 41 patients with pulmonary hypertension 25 patients were 
dyspneic; 5 had a palpable P2 and 6 a loud P2 ; 4 had an RV lift; 2 
had pedal edema; and 4 had a raised JVP. In 1 case the ECG had 
evidence of RA and RV enlargement. On the radiograph 7 were 
thought to have enlarged pulmonary arteries and 4 enlarged right 
ventricles; only 3 cases had a right descending pulmonary artery 
more than 15 mm. (This measurement was possible in 59 
radiographs.) 
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2.7.14 Other forms of Pulmonary Involvement in SLE 
Pleural involvement had occurred at some time in their history in 
25 patients (37.9%). In these patients 80% had experienced chest 
pain, 24% had an audible rub, 60% clinical evidence of an effusion 
and 80% radiological evidence of pleural involvement. 
Pulmonary infections had occurred in 38 patients (57.6%). The 
commonest was bronchitis occurring in 27 (multiple in 15). 
Pneumonia had occurred in 16 (13 needing a single admission, and 3 
needing 2, 3 and 6 admissions respectively). Pulmonary 
tuberculosis had occurred in 5. 
The patients with infections had received immunosupressives for a 
mean of 54.3 months. In contrast, the patients without infections, 
had received it for a mean of 34.3 months. This difference was not 
significant. (Chi-square approx. p=0.1990) The smoking history was 
similar for the patients with infections (mean 4.68 pack-year) and 
without infections (mean 3.52 pack-year; Chi-square approx. 
p=0.851) 
Cryptogenic fibrosing alveolitis was present in 9 (13.6%). 7 (78%) 
had a cough, 5 (56%) were dyspneic, none were clubbed, and all had 
end-inspiratory crackles. Chest radiograph revealed small lungs in 
6 (67%) and an infiltrate in 8 (89%). Pulmonary function tests 
confirmed restriction in 8 (89%) and all had a reduced TLCO. Only 
1 case had a bronchoscopy performed to confirm the diagnosis. 
Vanishing lung was present in 3 (4.6%); all were dyspneic, had 
small lungs on CXR and had markedly reduced MIP's and MEP's. 
Pulmonary thromboembolism, unrelated to the antiphospholipid 
antibody syndrome, had previously been confirmed in 1 patient 
(1.5%) by ventilation/perfusion scanning. 
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Other forms of pulmonary involvement included: acute lupus 
pneumonitis in 2, pulmonary hemorrhage in 1, asthma in 6, smoking 
induced COAD in 1, bronchiectasis in 1, and a solitary pulmonary 
nodule (probably a granuloma) in 2. 
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Chapter 3 DISCUSSION OF RESULTS 
3.1 Statistical Analysis 
3.1.1 Pulmonary Artery Pressures in SLE 
The mean pulmonary artery pressure of SLE patients was 
significantly higher than in control subjects (25.90 vs 15.72; Chi 
square approximation test, p = 0.0001) 
3.1.2 Association between the presence and severity of Raynaud's 
Phenomenon and Pulmonary Hypertension (Table 3.1) 
There was no difference in the presence of Raynaud's phenomenon 
whether current or past, or in the Raynaud's severity score, 
between the patients with pulmonary hypertension and those 
without. Similarly no differences were noted with respect to 
Raynaud's and the pulmonary artery pressure subgroups. 
PH Total 
No PH 
Possible 
Probable 
Definite 
Fisher's exact 
PA Pressure 
<20 
20 - 40 
>40 
Table 3.1 
Raynaud's in PH groups 
Number presence of Rayn. 
(N cases) 
25 13 
21 14 
12 5 
8 6 
test p = 0.185 
N severity > 1 
25 4 
33 9 
8 3 
Chi-square approx. p = 0 . 395 
severity > 1 
(N cases) 
4 
6 
3 
3 
p = 0.457 
3.1.3 Association between Disease Activity and PH (Table 3.2) 
The different pulmonary hypertension groups did not differ with 
respect to the physician's global assessment of disease activity. 
However there was a trend towards a higher disease activity score 
in patients with higher PA pressures (Chi square approx.; 
p=0.0642) 
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Table 3.2 
Disease activity score in Pulmonary Hypertension groups 
PH N mean activity score 
No PH 25 2.69 
Possible 21 3.16 
Probable 12 3.25 
Definite 8 3.63 
Chi-square approx. p = 0.1583 
PA pressure N mean activity score 
<20 25 2.68 
20 - 40 33 3.18 
>40 8 3.63 
Chi-square approx. p = 0.0642 
3.1.4 Differences in Clinical features and Laboratory parameters 
between the pulmonary hypertension groups (Table 3.3, 3.4, 3.5) 
In the different pulmonary hypertension groups a significant 
difference in the uncorrected TLCOsbi and in the CXR right 
pulmonary artery diameter was noted. The TLCO was lowest in 
"probable" and "definite PH" as can be expected. The low TLCO 
level of the "No PH" group is probably due to the inclusion of 
patients with fibrosing alveolitis in this group. The differences 
in the PA diameter can possibly also be explained on this basis. 
See Table 3.3 
Table 3.3 
TLCO and PA diameter in PH 
PH mean TLCO (% pred) mean right PA diam. 
No PH 70.02 g. 0 12.6 mm. 
Possible 91.90 g. 0 10.9 mm. 
Probable 52.98 % 13 . 8 mm . 
Definite 63 . 87 g. 0 12 . 1 mm. 
Chi-square approx . p = 0.0163 p = 0.0268 
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The total ARA criteria in the different groups almost reached 
significance. See Table 3.4 
Table 3.4 
ARA criteria in PH 
PH N mean total ARA criteria 
No PH 25 5.50 
Possible 21 6.47 
Probable 12 6.17 
Definite 8 6.63 
Chi-square approx. p = 0.0717 
No significant difference was noted between the PH groups with 
respect to the miscellaneous variables shown in Table 3.5. 
Table 3.5 
Miscellaneous variables and the PH groups 
Variable Test p-value 
Dyspnea score Chi-square approx. 0.5282 
Disease(Durat) Chi-square approx. 0.6286 
Smoking(curr) Fisher's Exact 0.527 
Smoking(past) Fisher's Exact 1.000 
Anticoag. Fisher's Exact 1. 000 
Immunosupp. Chi-square approx. 0.6374 
Chloroquine Chi-square approx. 0.5931 
Vasodil. Fisher's Exact 0.776 
Dig. ulcer. Fisher's Exact 0.951 
FEVl Chi-square approx. 0.3987 
FVC Chi-square approx. 0.6168 
Anti-DNA Chi-square approx. 0.8401 
C-RP Chi-square approx. 0.2575 
CH50 Chi-square approx. 0.9264 
C3 Chi-square approx. 0.2711 
C4 Chi-square approx. 0.7736 
CIC Chi-square approx. 0.4086 
APL Chi-square approx. 0.8169 
wee Chi-square approx. 0.7168 
Lymph. Chi-square approx. 0.8318 
45 
3.1.5 Differences in Clinical features and Laboratory parameters 
according to PA pressure level (Table 3.6. 3.7) 
In the different pulmonary artery pressure groups there was a 
significant difference in the total number of ARA criteria. See 
Table 3.6 
Table 3.6 
ARA criteria in PA pressure groups 
PA pressure N mean total ARA criteria 
<20 25 5.44 
20 - 40 33 6.30 
>40 8 6.63 
Chi-square approx. p = 0.0440 
There was no significant difference between the groups with 
respect to the variables shown in Table 3.7. 
Table 3.7 
Miscellaneous variables and the PA pressure groups 
Variable Test p-value 
Disease(durat) Chi-square approx. 0.6059 
Smoking(curr) Chi-square approx. 0.932 
Smoking(past) Chi-square approx. 0.917 
Anticoag. Fisher's Exact 1.000 
Immunosupp. Chi-square approx. 0.5705 
Chloroquine Chi-square approx. 0.5773 
Vasodil. Fisher's Exact 0.817 
Dig. ulcer . Fisher's Exact 1.000 
FEVl Chi-square approx. 0.2699 
FVC Chi-square approx. 0.5133 
TLCO(uncorr) Chi-square approx. 0.2744 
Anti-DNA Chi-square approx. 0.5991 
C-RP Chi-square approx. 0.1859 
CH50 Chi-square approx. 0.5007 
C3 Chi-square approx. 0.4979 
C4 Chi-square approx. 0.5721 
CIC Chi-square approx. 0.5319 
APL Chi-square approx. 0.6795 
wee Chi-square approx. 0.2495 
Lymph. Chi-square approx. 0.7940 
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3.2 Discussion 
3.2.1 Pulmonary Hypertension in Systemic Lupus Erythematosus 
41 (62%) of the 66 patients studied were shown to have 
echocardiographic evidence of altered pulmonary blood flow 
velocities and/or altered transtricuspid pressure gradients 
compatible with pulmonary hypertension. Estimates of pulmonary 
artery pressure made upon the basis of these variables provided 
categorisation of 12 patients (29%) as having definite primary 
pulmonary hypertension, 18 (44%) as probable primary pulmonary 
hypertension and a further 11 (27%) as secondary pulmonary 
hypertension. Recognising the limitations of the 
echocardiographically derived pulmonary artery pressures, 
discussed in chapter 3.3.1, the study seems to support the 
observations made previously of an increased incidence of 
pulmonary hypertension not explained by other forms of lung 
disease in SLE. 20 - 27 The finding of significantly lower pressures 
in the normal volunteers acting as controls, further strengthens 
this conclusion. 
Support for the concept that the higher than expected incidence of 
pulmonary hypertension is the result of occult pulmonary vascular 
disease, is the disproportionate reduction in the TLCOsb in 
patients with SLE compared with reduction in lung volumes. The 
majority of patients had normal or only mildly reduced volumes but 
the TLCOsb was reduced by a greater percentage overall. 25% of 
patients had moderate to severely reduced TLCOsb' even when 
corrected for hemoglobin. The latter correction increased the 
TLCOsb from a mean of 15.64 to 17.54. (p=0.0001) Thus anemia, a 
common problem in SLE, was responsible for a significantly reduced 
TLCOsb· The remainder may be the result of pulmonary vascular 
disease. 
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The definitions of possible, probable and definite pulmonary 
hypertension used in this study, were defined according to 
currently accepted non-invasive tests. 39 , 40 They need to be 
validated by larger studies with direct measurement of pulmonary 
artery pressure. This study confirmed the low sensitivity of 
physical signs and other non-invasive tests. 
The pulmonary artery measurements could have been validated with 
right heart catheter data, but this would have made the study more 
invasive, and less acceptable to the patients. They are further 
supported by the normal values found in normal controls. 
3.2.2 The association between Raynaud's phenomenon and pulmonary 
hypertension 
The results of this study do not support the second hypothesis 
that pulmonary hypertension is strongly associated with peripheral 
vasospasm. Raynaud's occurred in 52% of patients with no pulmonary 
hypertension, 67% of possible, 42% of probable and 75% of definite 
pulmonary hypertension. 
The study failed to show an association between current or past 
digital ulceration and pulmonary hypertension. It is unlikely that 
the use of vasodilators could have masked the association as 
similar proportions of patients in each PH group were on 
vasodilators. 
3.2.3 The association between disease activity and pulmonary 
hypertension 
Various disease activity indices have been devised in SLE using 
combined clinical and laboratory parameters. 79 , 80 These indices 
were considered too time consuming for use in this study. An 
attempt at an approximate allocation of disease activity was 
however made, firstly, with the individual laboratory 
investigations available and, secondly, the physician's global 
assessment using the combined clinical and laboratory findings 
listed in Chapter 2.4.6. 
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The study failed to find an association between pulmonary 
hypertension and indices of disease activity in SLE. There was a 
trend toward an association of the physician's global assessment 
of disease activity and increasing certainty of PH: no PH, 
possible, probable, to definite PH, but this did not reach 
statistical significance. (p=0.1583) The global assessment of the 
three pressure groups showed a similar trend, but still did not 
reach significance. (p=0.0642) 
It is possible that these trends are the result of observer bias 
as the study was not blinded. Thus higher activity scores may have 
been allocated to cases with pulmonary hypertension and higher PA 
pressures, even though these were not included in the original 
list of activity markers. Alternatively the results may support 
the hypothesis, but failed to reach statistical significance 
because the numbers were too small especially in the "definite" 
and ">40" pressure groups. 
3.2.4 The association between total ARA criteria and pulmonary 
hypertension 
The total number of ARA diagnostic criteria in the pulmonary 
artery pressure groups reached significance. (p= 0.044) The total 
criteria in the different pulmonary hypertension groups almost 
reached significance. (p= 0.0717) 
The higher total criteria is often said to reflect disease 
duration. Comparing the pulmonary hypertension and pulmonary 
artery pressure groups with disease duration, however, failed to 
show such a tendency. 
The number of criteria generally increases as the disease involves 
more systems. The tendency described above may therefore reflect 
the fact that SLE, being a multisystem disorder, affects more 
organs as it progresses, and that pulmonary hypertension occurs as 
part of this multisystem disease. 
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3.2.5 Other pulmonary involvement found in study patients 
Pulmonary infections occur commonly in patients with SLE. The 
commonest infection in this study was bronchitis. It is likely 
that the 27 cases recorded is an underestimate, as many infections 
would have been treated by private practitioners, and not reported 
in the hospital folders. Pneumonia occurred in 16 cases, with 
multiple admissions in 3. Despite the high local prevalence of 
tuberculosis, only 5 cases had been treated for pulmonary 
tuberculosis. 
The reason for frequent infections is probably multifactorial: 
decreased immunity which is well recognised in SLE; treatment with 
immunosupressives; smoking; and underlying lung disease may all 
play a role. We were unable to confirm these associations in this 
study. 
Pleural involvement occurred in a third of the patients. This too 
might be an underestimate, as pleural disease may be transient and 
self-limiting and the signs may thus be missed. Several CXR's and 
reports were also missing, contributing to a possible 
underestimate of radiologically confirmed pleural involvement. 
Cryptogenic fibrosing alveolitis occurred in 9 patients (13.6%). 
The clinical features were similar to "lone CFA" ie. CFA occurring 
without a collagen vascular disorder. The only exception was the 
absence of clubbing found in the SLE patients. 5 cases were on 
treatment with corticosteroids, alone, or in combination with 
azathioprine. 
Vanishing lung, a well recognised pulmonary manifestation of 
SLE 81 , is thought to result from a combination of diaphragmatic 
weakness, pleural thickening, and basal parenchymal fibrosis. 
Three patients were identified, and in one it was successfully 
treated with corticosteroids. 
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Only one patient with pulmonary thromboembolism was identified . In 
view of the reported high prevalence of the lupus anticoagulant in 
SLE, 82 (40% in this series) more cases of thromboembolism might 
have been expected. However, the concentrations of APL was a low 
titre in half, and only moderate titre in the remainder . Minor 
episodes of thromboembolism may easily be missed, or the diagnos i s 
overlooked as chest pain is a common occurrence in SLE, and is not 
routinely investigated. Minor dyspnea may also be attributed to 
anemia, or inactivity, which is often seen in chronically ill 
patients. However, in the few patients with elevated pulmonary 
artery pressures in whom perfusion scans were performed, no 
evidence of pulmonary thromboembolism were found . 
The single case of pulmonary hemorrhage was confidently diagnosed 
on clinical evidence of episodic minor hemoptysis, dyspnea, iron 
deficiency anemia, and transient alveolar filling patterns on CXR . 
3.3 Limitations and short-comings of the current study 
3 . 3 . 1 Measurement of pulmonary artery pressures 
A criticism of the study is that in most patients (51) tricuspid 
regurgitation(TR) could not be found in the echocardiography 
laboratory, necessitating calculation of the mean PA pressure from 
the less accurate AcT and RVET methods. In only 9 was the 
pulmonary artery pressure derived from TR. This low pick- up rate 
of TR may be the result of relative lack of observ er skill, or 
perseverance due to time constraints, or due to a true low 
i ncidence of TR. 
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In the majority of patients, the pulmonary artery pressures were 
derived from the AcT and RVET described in chapter 1 . 3.10. This 
method has important limitations: 
-The AcT and RVET are measures of intracardiac blood-flow 
velocities that are altered by pressure changes, but also by 
changes in heart rate and haematocrit. The influence of the 
latter variables were not specifically looked at, and may have 
affected the measurements of the patients, and not of the 
normal controls. 
-The AcT and RVET measurements may vary from beat to beat, and 
the average from 4 - 5 cardiac cycles were used. Some studies 
report using up to 11 cardiac cycles for these measurements. 
Had we used 11 cycles, the results may have been more accurate, 
but 5 cycles were regarded as adequate. 
-Finally, the measurement of AcT and RVET are not routinely 
performed in our echocardiography laboratory, and are operator 
dependent. Inter- and intra-observer variability should 
therefore have been tested for, and ideally compared with 
invasively measured right heart pressures to validate the 
results obtained from our echocardiography laboratory. 
3.3.2 Exclusion of alternative causes of Pulmonary Hypertension 
The distinction between 1 O and 2 O pulmonary hypertension is 
important, as different pathogenetic mechanisms are involved, and 
treatment will differ. Pulmonary thromboembolism was not excluded 
by pulmonary angiograms or V/Q scans in all patients with 
pulmonary hypertension, as there was often no clinical suspicion 
of this condition. This weakens the study, as recurrent pulmonary 
thromboemboli may be asymptomatic. However, the probability of 
pulmonary thromboemboli accounting for the majority of patients 
with pulmonary hypertension in this study seem low . 
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In SLE, the variety of other forms of lung involvement that may be 
present, makes the study of isolated pulmonary vascular disease 
more difficult. The high incidence of these other lung conditions 
(37.9% had past history of pleural involvement, 57.6% pulmonary 
infections, 13.6% CFA and 4.6% vanishing lung) means that it is 
advisable to assume that such conditions, in a high proportion of 
cases, might have contributed to the development of apparently 
isolated pulmonary hypertension. In this study reasonable although 
not exhaustive attempts were made to recognise 2 O PH occurring in 
the presence of likely thromboembolism or interstitial lung 
disease or cardiac disease. However, minor degrees of these might 
have been present. It remains speculative whether more invasive 
and expensive testing would have provided a more useful result, 
albeit more accurate. For interstitial lung disease, an open lung 
biopsy might be useful; in pulmonary thromboembolism, a V/Q lung 
scan and pulmonary angiogram would be viewed as definitive 
confirmation; and for heart disease, a cardiac catheterisation 
would have ensured greater certainty about the contributions of 
these conditions to pulmonary hypertension. It is worth noting 
that in the CFA group the mean PA pressure was 30 mm Hg and that 1 
patient had a mean PA pressure> 40 . The cost of performing full 
ventilation/perfusion scans as part of this study, especially in 
the asymptomatic individuals, could not be justified. This 
significantly reduced the confidence with which cases were 
classified as 1 O or 2 O pulmonary hypertension. 
3.4 Conclusions and recommendations for future research 
This study has confirmed the frequent involvement of the lung in 
SLE, and using the echocardiograph has identified intracardiac 
blood-flow velocity alterations compatible with pulmonary 
hypertension in a higher proportion of patients than previously 
recognised . In most patients this appeared to represent specific 
involvement of the pulmonary vasculature rather than being due to 
other forms of lung disease . As perfusion lung scans were not 
performed in all the cases, the role of thromboembolism can not be 
excluded. However, positive confirmation of thromboembolism was 
present in only one case. 
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Contrary to expectations, no association between the presence of 
Raynaud's phenomenon or digital ulceration, (considered to be 
indicators of peripheral vasospastic activity) and pulmonary 
hypertension was observed. In addition the presence of pulmonary 
hypertension bore no relationship to indicators of disease 
activity. The severity of pulmonary hypertension, however, 
appeared to relate positively to the extent of multisystem 
involvement in SLE. 
The usefulness of certain diagnostic criteria for PH was 
disappointing. For example, although in patients with relatively 
isolated pulmonary vascular involvement, the reduction in TLCOsb 
and diameter of the right descending pulmonary artery on CXR both 
bore a positive relationship to severity of PH, these features 
were of less value in all patients with SLE, as they were 
adversely affected by other forms of lung disease present in the 
patients eg. CFA, vanishing lung syndrome and pulmonary 
thromboembolism. 
The common occurrence of PH in SLE raises questions about 
appropriate follow-up and treatment. Follow-up studies of the 
natural history and longterm prognosis of PH in SLE are required. 
Our experience has confirmed that in several patients the disease 
is progressive and fatal. Echocardiography provides a safe, non-
invasive method for following the course of pulmonary vascular 
involvement and the efficacy of treatment. With further 
refinements of non-invasive technology, right heart catheter 
confirmation of PH will become less necessary. However, pulmonary 
angiography and perfusion lung scans should be used more 
frequently to exclude recurrent pulmonary thromboembolism. 
54 
Another future avenue of research should be to attempt to identify 
SLE patients at risk of developing PH at a stage when it may be 
detected only as inducible pulmonary vasospasm. The change in the 
membrane and capillary component of TLCOsb during a cold pressor 
test, may identify cases with pulmonary vasospasm. Double blind, 
randomised control studies will then be needed to assess the 
long term effects of early treatment of patients identified in 
this manner. 
Currently treatment with anticoagulants and vasodilators are 
advised only for patients with established PH. Patients with 
significant interstitial lung disease might in addition benefit 
from corticosteroids alone or in combination with azathioprine or 
cyclophosphamide. 
In conclusion, I believe that the main value of the study was the 
early detection of minor degrees of elevation of the pulmonary 
artery pressure in a significant number of patients with SLE. 
These patients have not yet developed irreversible vascular damage 
and will be the subject of future research. 
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APPENDIX B 
Laboratory Reference Values 
ANF: 
Anti-DNA: 
APL-IGG: 
C3: 
C4: 
CH50: 
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C-RP: 
ENA: 
Hb: 
Lymph: 
Platelets: 
PTT: 
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VDRL: 
WCC: 
>/= 40 
0 - 15 ug DNA 
0 - 10 u/ml 
10 - 20 u/ml 
20 - 100 u/ml 
> 100 u/ml 
85 - 195 mg/ml 
12 - 36 mg/ml 
bound/ml serum 
normal 
low titre 
moderate titre 
high titre 
160 - 220 mg/ml 
0 - 7% 
undetectable mg% 
0 - 320 
11. 6 - 15. 6 g/gl 
1.2 - 4.0 X 10 /1 
164 - 432 X 10 9 /1 
> 1.5 Control 
negative 
negative 
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APPENDIX C 
Pulmonary Function Tests 
Normal Mild Moderate Severe 
FEVl > 80 60 - 79 41 - 59 < 
FVC > 80 60 - 79 51 - 59 < 
Ratio > 75 60 - 74 41 - 59 < 
TLCO > 80 60 - 79 41 - 59 < 
Values are expressed as% predicted. 
Hb Corrected TLCOsb formula77 
Hb Corrected TLCO = 
Smoking History 
Observed TLCO x (10.22 + Hb) 
1.7xHb 
40 
50 
40 
40 
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1 Pack-year= one packet of 20 cigarettes per day for one 
year 
APPENDIX D 
CONSENT FORM 
I, hereby give my consent to 
be 
73 
involved in this clinical study. I understand that this 
consent is voluntary and that my future care will not be 
prejudiced should I not agree to the study. 
All the information gathered will be used for research 
purposes and I agree to it being published in medical 
journals or presented at clinical meetings provided the 
investigators adhere to accepted standards of medical 
confidentiality. 
Signed on 
Subject: 
Witness: 
/ /199 at Groote Schuur Hospital. 
